Our studies involve people who have memory problems like mild cognitive impairment, Alzheimer’s disease and other types of dementia.\u00a0 They often involve family members or someone who knows them well.<\/p>\n
Every study is different and designed for different groups of people. <\/span>Some involve a questionnaire, some involve a therapy and some involve taking a medication.\u00a0 Some studies take place at home and some take place in our research clinics. They broadly fall into the following categories:<\/p>\n Clinic Based Drug Studies<\/strong><\/p>\n Biomarker Studies<\/strong><\/p>\n Therapy or Intervention Studies<\/strong><\/p>\n We are sometimes able to contact people directly about research, but we always appreciate hearing from people who are interested in getting involved.<\/span><\/p>\n MINDSET: A Study to look at the Safety and Effectiveness of KarXT in Alzheimers’ Cognition<\/strong><\/p>\n Principal Investigator: Dr Qi Pei – Consultant Psychiatrist<\/span><\/p>\n Chief Investigator: Professor Vanessa Raymont, Honorary Consultant Psychiatrist and R&D Director, Oxford Health NHS Foundation Trust, Department of Psychiatry, University of Oxford\u00a0<\/span><\/p>\n _______________________________________________<\/span><\/p>\n COBALT: Combining memantine and cholinesterase inhibitors in Lewy Body dementia and Parkinson Disease dementia, recruiting participants aged 55+ with a diagnosis of Lewy body Dementia or Parkinson\u2019s Disease Dementia.<\/strong><\/p>\n Principal Investigator: Dr Qi Pei – Consultant Psychiatrist, Oxford Health NHS Foundation Trust<\/span><\/p>\n _______________________________________________<\/span><\/p>\n ISAP:\u00a0The ISAP Study will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at risk of developing Alzheimer\u2019s dementia.\u00a0 <\/span>Recruiting participants aged 55+ with no memory issues or minimal mild cognitive impairment.<\/strong><\/p>\n Principal Investigator: Dr Ivan Koychev – Senior Clinical Researcher, Consultant Neuropsychiatrist<\/p>\n <\/span><\/p>\n ON-FIRE:\u00a0 Open Network for Frontotemporal dementia Inflammation REsearch\u00a0<\/strong><\/p>\n Principal Investigator: Zoe Collett, Clinical Research Facilitator, Oxford Health NHS Foundation Trust<\/p>\n _______________________________________________<\/span><\/p>\n READ-OUT: Assessing the usefulness of blood-based tests for dementia and whether they a good use of money for the NHS. Recruiting individuals aged 45+, with a memory problem diagnosis or presenting to a clinician with memory complaints.<\/strong><\/p>\n Principal Investigator: Professor Vanessa Raymont, Honorary Consultant Psychiatrist and R&D Director, Oxford Health NHS Foundation Trust, Department of Psychiatry, University of Oxford\u00a0<\/span><\/p>\n _______________________________________________<\/span><\/p>\n SHINE: Investigating the use of different scans (M\/EEG, MRI, lumbar puncture, PET scan) to identify biomarkers of Alzheimer\u2019s Dementia for diagnosis and prediction of disease. Recruiting individuals aged 50-85 with or without a dementia diagnosis.<\/strong><\/p>\n Principal Investigator: Professor Vanessa Raymont, Honorary Consultant Psychiatrist and R&D Director, Oxford Health NHS Foundation Trust, Department of Psychiatry, University of Oxford<\/p>\n <\/span><\/p>\n Being kind to ourselves: A randomised controlled trial of Compassion Focused Therapy (CFT) to improve symptoms of depression and anxiety in Dementia<\/strong><\/p>\n Principal Investigator: Dr Catriona Craig, Principal Clinical Psychologist, Buckinghamshire Older People\u2019s Psychological Services, Oxford Health NHS Foundation Trust <\/span>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/span><\/p>\n <\/p>\n The people who signed up continue to be involved in study interventions\/ assessments.<\/span><\/p>\n POLARIS AD: This phase 3 clinical trial is investigating a new potential therapy for early signs of Alzheimer’s Disease, recruiting participants aged 55-90 with an Alzheimer\u2019s Diagnosis.<\/strong><\/p>\n Principal Investigator: Professor Vanessa Raymont, <\/span>Honorary Consultant Psychiatrist and R&D Director, Oxford Health NHS Foundation Trust, Department of Psychiatry, University of Oxford<\/p>\n Sub I: Dr Qi Pei – Consultant Psychiatrist PREVENT Dementia: Aiming to identify the earliest signs of dementia.<\/strong><\/p>\n Principal Investigator: Dr Ivan Koychev – Senior Clinical Researcher, Consultant Neuropsychiatrist<\/span><\/p>\n _______________________________________________<\/span><\/p>\n Brains for dementia<\/strong> research: A longitudinal cohort study of planned brain donation.\u00a0 A world-class brain tissue resource supporting dementia research.<\/strong><\/p>\n\n
\n
\n
\n Click here for current studies<\/span>\n <\/summary>\n
These studies are currently open to new participants:<\/h2>\n
\nClinic Based Drug Studies<\/strong><\/span><\/h3>\n
\nBiomarker studies:<\/strong><\/h3>\n
\nTherapy or Intervention Studies:<\/h3>\n
\nThese studies have completed the recruitment phase:<\/strong>\u00a0\u00a0<\/span><\/h2>\n
\n<\/span>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 _______________________________________________<\/span><\/strong><\/p>\n